<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04867369</url>
  </required_header>
  <id_info>
    <org_study_id>20-01978</org_study_id>
    <nct_id>NCT04867369</nct_id>
  </id_info>
  <brief_title>Pecs II Block Versus Surgeon Infiltration for Open Subpectoral Biceps Tenodesis</brief_title>
  <official_title>Pecs II Block Versus Surgeon Infiltration for Open Subpectoral Biceps Tenodesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase IV, randomized, single-blind, single-center study measuring the effects of Pecs II&#xD;
      block with 0.25% bupivacaine versus surgeon infiltration with 0.25% bupivacaine on&#xD;
      postoperative pain control and opioid utilization in participants who undergo open&#xD;
      subpectoral tenodesis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 14, 2021</start_date>
  <completion_date type="Anticipated">August 7, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 3, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Opioid utilization for the first 24 hours after surgery, including during surgery, calculated as oxycodone equivalent</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient reported Visual Analog Scale (VAS) scores in PACU</measure>
    <time_frame>24 hours</time_frame>
    <description>The visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between &quot;no pain&quot; and &quot;worst pain.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported Visual Analog Scale (VAS) score at postoperative day 1 (POD 1)</measure>
    <time_frame>24-48 hours</time_frame>
    <description>The visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between &quot;no pain&quot; and &quot;worst pain.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported Visual Analog Scale (VAS) score at postoperative day 3 (POD 3)</measure>
    <time_frame>72 hours</time_frame>
    <description>The visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between &quot;no pain&quot; and &quot;worst pain.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of patient reaction to surgical subpectoral incision</measure>
    <time_frame>24 hours</time_frame>
    <description>signs include patient movement, tachycardia, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence or absence of sensation to cold and pinprick in PACU</measure>
    <time_frame>24 hours</time_frame>
    <description>Alcohol skin testing in the axilla (distal to surgical dressing) will be done in PACU prior to discharge to evaluate the presence or absence of sensation to cold and pinprick in that area.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Tendonitis</condition>
  <arm_group>
    <arm_group_label>Pecs II block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 patients scheduled for open biceps tenodesis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgical infiltration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>80 patients scheduled for open biceps tenodesis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pecs II block</intervention_name>
    <description>Patients will receive an interscalene nerve block with 15 mL 0.5% bupivacaine + a Pecs II fascial plane block with 20 mL 0.25% bupivacaine</description>
    <arm_group_label>Pecs II block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Surgical infiltration</intervention_name>
    <description>Patients will receive an interscalene nerve block with 20 mL 0.5% bupivacaine + local infiltration of 0.25% bupivacaine by the surgeon, up to 15 mL</description>
    <arm_group_label>Surgical infiltration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients between 18 and 75 years of age&#xD;
&#xD;
          2. Patients undergoing shoulder arthroscopy with open subpectoral biceps tenodesis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients younger than 18 and older than 75;&#xD;
&#xD;
          2. Patients with a history of chronic pain that have used opioids for pain management for&#xD;
             3 months or longer;&#xD;
&#xD;
          3. Patients who are allergic to oxycodone;&#xD;
&#xD;
          4. Patients with diagnosed or self-reported cognitive dysfunction;&#xD;
&#xD;
          5. Patients with a history of neurologic disorder that can interfere with pain sensation;&#xD;
&#xD;
          6. Patients with a history of drug or recorded alcohol abuse;&#xD;
&#xD;
          7. Patients who are unable to understand or follow instructions;&#xD;
&#xD;
          8. Patients with severe liver disease, renal insufficiency, congestive heart failure,&#xD;
             and/or significant heart disease;&#xD;
&#xD;
          9. Patients with an allergy or contraindication to any of the medications used in the&#xD;
             study, or patients with a contraindication to any study procedures;&#xD;
&#xD;
         10. Patients with a BMI over 45;&#xD;
&#xD;
         11. Any patient that the investigators feel cannot comply with all study related&#xD;
             procedures;&#xD;
&#xD;
         12. NYU Langone Health students, residents, faculty or staff members.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Uchenna Umeh, MD</last_name>
    <phone>212-598-6085</phone>
    <email>Uchenna.Umeh@nyulangone.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ekow Commeh</last_name>
    <phone>212-263-3851</phone>
    <email>Ekow.commeh@nyulangone.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uchenna Umeh, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 28, 2021</study_first_submitted>
  <study_first_submitted_qc>April 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2021</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tendinopathy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: Uchenna.Umeh@nyulangone.org. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months following article publication or as required.</ipd_time_frame>
    <ipd_access_criteria>Requests may be directed to Uchenna.Umeh@nyulangone.org.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

